NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=163228&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=163230&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=163231&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

From ‘Right to Try’ to Cannabis: Trump’s Next Breakthrough Could Unlock FDA Trials. "President Trump’s marijuana decision must go beyond politics-patients suffering from Huntington’s disease and Multiple Sclerosis have waited nearly a decade for access to MMJ International Holdings’ FDA-approved clinical trials. With capsules manufactured and science in place, all that’s missing is the DEA

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=163232&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=163234&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=163233&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=163236&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=163235&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 24, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=163238&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or